TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25694350

Group type: EXPERIMENTAL
Intervention: 400 IU/d vitamin D3
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 800 IU/d vitamin D3
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 1200 IU/d vitamin D3
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 76

Group type: COMPARATOR
Intervention: 0 IU/d vitamin D3 (placebo)
Number of subjects: 76
Study: 25239718

Group type: EXPERIMENTAL
Intervention: Early intervention group (audit and feedback intervention for frontline nurses)
Number of subjects: 13499

Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 13499

Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 13499

Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 13499
Study: 22966164

Group type: EXPERIMENTAL
Intervention: Lifelong active elderly
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lifelong sedentary elderly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tyramine infusion
Number of subjects: 24
Study: 20456484

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP, 500 microg b.i.d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17507322

Group type: EXPERIMENTAL
Intervention: etravirine 800 mg bid
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: etravirine 400 mg bid
Number of subjects: 199

Group type: COMPARATOR
Intervention: control
Number of subjects: 199
Study: 16286387

Group type: EXPERIMENTAL
Intervention: Low-dose oral corticosteroids (CS) used by 13 RA patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: No corticosteroid treatment (RA patients without CS and healthy controls)
Number of subjects: 42
Study: 12401595

Group type: EXPERIMENTAL
Intervention: IV fentanyl (10 micro g/kg bolus followed by 10 micro g. kg(‐1). h(‐1) infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (2 micro g/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined IV and IT fentanyl protocols
Number of subjects: 30

Group type: COMPARATOR
Intervention: IV fentanyl (10 micro g/kg bolus and 10 micro g. kg(‐1). h(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined IV and IT protocols
Number of subjects: 30
Study: 12198783

Group type: EXPERIMENTAL
Intervention: Presence of colored target elements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of spatially distinct color word distractor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contextually controlled skilled word recognition
Number of subjects: 0
Study: 7885801

Group type: EXPERIMENTAL
Intervention: Detection of any (target-nontarget) difference in the display (heterogeneity/homogeneity decision)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elimination of one potential source of difference (noncritical difference requiring a negative response)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance knowledge of the likely source of difference
Number of subjects: 0
Study: 2297150

Group type: EXPERIMENTAL
Intervention: Metaproterenol (Alupent inhalation solution)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study: 364333

Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Meglumine ioxithalamate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 51
Study: 6125394

Group type: EXPERIMENTAL
Intervention: Single daily doses of clobazam
Number of subjects: 114

Group type: COMPARATOR
Intervention: Divided daily doses of clobazam
Number of subjects: 114
Study: 31499563

Group type: EXPERIMENTAL
Intervention: High-frequency PA breaks (HIGH-FREQ) consisting of 15 ×2 min bouts of moderate-intensity treadmill PA every 30 min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-frequency PA breaks (LOW-FREQ) consisting of 3 ×10 min bouts of moderate-intensity treadmill PA every 180 min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prolonged sitting (SIT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-frequency PA breaks (LOW-FREQ)
Number of subjects: 14
Study: 29576505

Group type: EXPERIMENTAL
Intervention: Siponimod 2 mg once daily
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Siponimod
Number of subjects: 1651
Study: 26909792

Group type: EXPERIMENTAL
Intervention: EndoPredict (EP) test
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: PAM50 risk of recurrence (ROR) scores (ROR-S)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: PAM50 risk of recurrence (ROR) scores (ROR-P)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: ROR-T (ROR-S, tumor size)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: ROR-PT (ROR-P, tumor size)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: EPclin (EP, tumor size, nodal status)
Number of subjects: 536
Study: 25029702

Group type: EXPERIMENTAL
Intervention: Dairy meal (3 servings providing 1350 mg calcium)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control meal (no dairy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dairy meal
Number of subjects: 32
Study: 22833447

Group type: EXPERIMENTAL
Intervention: 1 hour of Battlemind Training module
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Survey-only control group
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Battlemind Training module
Number of subjects: 1645
Study: 19580368

Group type: EXPERIMENTAL
Intervention: Inhaled cyclosporine (ACsA) 300 mg, 3 days a week for 2 years
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inhaled cyclosporine (ACsA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Aerosol placebo
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional immunosuppression (Novartis controls)
Number of subjects: 58
Study: 16750618

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with SM (15 mg/kg intramuscularly three times per week for the initial 3 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Combined chemotherapy without SM
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with SM
Number of subjects: 160
Study: 16246987

Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) of 30 mL/min or lower (<= 0.50 mL/s)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Creatinine clearance (CrCl) higher than 90 mL/min (> 1.50 mL/s)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Participants with CrCl of 30 mL/min or lower (<= 0.50 mL/s)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Moderate kidney impairment (CrCl between 30 mL/min and 90 mL/min)
Number of subjects: 1005
Study: 12172693

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg MDMA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg MDMA
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10444779

Group type: EXPERIMENTAL
Intervention: Ultrasonography guided puncture (UGP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Anatomically oriented puncture (AOP)
Number of subjects: 77
Study: 8545501

Group type: EXPERIMENTAL
Intervention: Hypnotized state with whole-body catalepsy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Resting wakefulness
Number of subjects: 15
Study: 2084208

Group type: EXPERIMENTAL
Intervention: TERM
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Hard-TERM
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cavit
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cavit-G
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cavit-W
Number of subjects: 144

Group type: COMPARATOR
Intervention: IRM-Caps
Number of subjects: 144

Group type: COMPARATOR
Intervention: Dentemp
Number of subjects: 144
Study: 504346

Group type: EXPERIMENTAL
Intervention: lithium sulphate (24‐36 mval/die)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 30127049

Group type: EXPERIMENTAL
Intervention: 50*10^6 MSCs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27034623

Group type: EXPERIMENTAL
Intervention: 1.5 g CrN (CrN-Low)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 3 g CrN (CrN-High)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 3 g CrM
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 61
Study: 26614627

Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery
Number of subjects: 808

Group type: COMPARATOR
Intervention: Manual phacoemulsification cataract surgery
Number of subjects: 808
Study: 23686322

Group type: EXPERIMENTAL
Intervention: Bimatoprost-timolol fixed combination (BTFC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 41
Study: 20950386

Group type: EXPERIMENTAL
Intervention: Immunologically active salivary substitutes for 6 months
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 134
Study: 18830857

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg for 24 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg and 8 mg)
Number of subjects: 41
Study: 16647684

Group type: EXPERIMENTAL
Intervention: 3-day hormone free interval (HFI)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Continuing active pills
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 21/7-day pre-extension cycle with heavier daily flow ratings
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 21/7-day pre-extension cycle with lighter daily flow ratings
Number of subjects: 111
Study: 14659770

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4IU every other day for 3 months
Number of subjects: 12
Study: 10716461

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 58
Study: 9491200

Group type: EXPERIMENTAL
Intervention: Dpt rush immunotherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study: 8412148

Group type: EXPERIMENTAL
Intervention: Alcohol (0.32 ml/kg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 2951819

Group type: EXPERIMENTAL
Intervention: Duovent (ipratropium bromide 40 mug and fenoterol 100 mug)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Berodual (ipratropium bromide 20 mug and fenoterol 50 mug)
Number of subjects: 21
Study: 29228230

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 170
Study: 27469556

Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: LLLT combined with aligners
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 21
Study: 25330837

Group type: EXPERIMENTAL
Intervention: DHEA 75 mg daily for three consecutive menstrual cycles prior to IVF cycles
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no DHEA treatment)
Number of subjects: 95
Study: 23194054

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with a blood glucose meter and 150 test strips
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no SMBG)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) after 1.5 years
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with more than three measurements per week
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no SMBG) after 1.5 years
Number of subjects: 124
Study: 20692119

Group type: EXPERIMENTAL
Intervention: Metal suture anchors
Number of subjects: 110

Group type: COMPARATOR
Intervention: Biodegradable suture anchors
Number of subjects: 110
Study: 18090035

Group type: EXPERIMENTAL
Intervention: Human placental extract (HPE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study: 16700374

Group type: EXPERIMENTAL
Intervention: Monotherapy with carbamazepine (Group A, n = 16)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined therapy with carbamazepine and phenytoin (Group B, n = 16)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No drugs (Group C, n = 18)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Overall comparison of congenital anomalies
Number of subjects: 50
Study: 12853784

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1 gm twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10768339

Group type: EXPERIMENTAL
Intervention: Entoptic perimetry
Number of subjects: 104

Group type: COMPARATOR
Intervention: Subjective impression
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amsler grid
Number of subjects: 104
Study: 8888916

Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cow's milk formula (CMF)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (CHF)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Family history of allergy
Number of subjects: 129
Study: 1511608

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6087129

Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-OP) treatment: 1 mg/ml solution, two drops, three times daily for one month
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soy flour treatment: 30 gm, three times daily for one month
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of CCK-OP and soy flour treatments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Secretin-pancreozymin test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Water and bicarbonate secretion
Number of subjects: 20
Study: 30713022

Group type: EXPERIMENTAL
Intervention: Individualized dosing with follitropin delta
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Conventional dosing with follitropin alfa
Number of subjects: 1326
Study: 30055373

Group type: EXPERIMENTAL
Intervention: Rating scale model (interval scale)
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Graded response model (no interval scale, ordered response categories)
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Partial credit model (no interval scale)
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Response categories associated with less pain
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Response categories associated with low pain intensity
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Response categories associated with high pain intensities
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Smallest response categories
Number of subjects: 2752
Study: 27115241

Group type: EXPERIMENTAL
Intervention: Simulated hearing loss (five degrees of hearing loss)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal hearing (control group)
Number of subjects: 125
Study: 24861828

Group type: EXPERIMENTAL
Intervention: Low-dose oral 17β-estradiol (0.5 mg/d)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Low-dose venlafaxine hydrochloride extended release (75 mg/d)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 22192960

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 20185000

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with BMI <30 kg/m²
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with BMI >=30 kg/m²
Number of subjects: 1231

Group type: COMPARATOR
Intervention: BMI <30 kg/m²
Number of subjects: 1231

Group type: COMPARATOR
Intervention: BMI decrease
Number of subjects: 1231
Study: 18060091

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg once daily
Number of subjects: 913

Group type: COMPARATOR
Intervention: Placebo (usual care minus inhaled anticholinergics)
Number of subjects: 913
Study: 15585213

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 7
Study: 12373467

Group type: EXPERIMENTAL
Intervention: APRV with spontaneous breathing
Number of subjects: 12

Group type: COMPARATOR
Intervention: APRV without spontaneous breathing (same V(E))
Number of subjects: 12

Group type: COMPARATOR
Intervention: APRV without spontaneous breathing (same Paw)
Number of subjects: 12
Study: 10335761

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 40 mg twice daily
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg twice daily
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg twice daily
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily for 6 months
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 80 mg twice daily for 3 months
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg once daily for 12 months
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Fexofenadine HCl (various doses)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Fexofenadine HCl
Number of subjects: 1160
Study: 7785008

Group type: EXPERIMENTAL
Intervention: Expiratory muscle training (EMT) for 15 minutes twice daily for four weeks using a pressure threshold device; expiratory threshold set at 30% of PEmax.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 12
Study: 1483317

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 26
Study: 4081404

Group type: EXPERIMENTAL
Intervention: Nalidixic acid (1 g X 3)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pivmecillinam (200‐400 mg X 3)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82
Study: 31252598

Group type: EXPERIMENTAL
Intervention: Caloric restriction by 20% of TDEE (CR I)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Caloric restriction by 30% of TDEE (CR II)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both CR I and CR II diets
Number of subjects: 94

Group type: COMPARATOR
Intervention: Comparison between CR I and CR II
Number of subjects: 94
Study: 30320676

Group type: EXPERIMENTAL
Intervention: Modified lateral tarsal strip (M‐LTS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional lateral tarsal strip (C‐LTS)
Number of subjects: 8
Study: 27163502

Group type: EXPERIMENTAL
Intervention: FF/LEVO (100/200 μg) as a fixed-dose combination (FDC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: FF (110 μg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: LEVO (200 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FF/LEVO FDC
Number of subjects: 30

Group type: COMPARATOR
Intervention: FF alone
Number of subjects: 30
Study: 25211749

Group type: EXPERIMENTAL
Intervention: Brief interactive intervention (n = 349)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Attention-equivalent control condition (n = 353)
Number of subjects: 702
Study: 22388527

Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs-Facilitation
Number of subjects: 50
Study: 20547984

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) 20 mg/m²/d plus chemotherapy (cisplatin and paclitaxel)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (cisplatin and paclitaxel)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus chemotherapy (cisplatin and paclitaxel)
Number of subjects: 107
Study: 18665031

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics (EMLA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ametop
Number of subjects: 41
Study: 16061839

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic 2.5% testosterone gel applied to scrotal skin (1 g, n = 54)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic 2.5% testosterone gel applied to non-scrotal skin (5 g, n = 56)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Androderm patches (2 patches/day, n = 52)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic 2.5% testosterone gel (scrotal and non-scrotal)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: All groups (scrotal gel, non-scrotal gel, patch)
Number of subjects: 162
Study: 11810598

Group type: EXPERIMENTAL
Intervention: Nucleoside analogues (NAs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: NAs only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stavudine and didanosine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HIV RNA level at month 30
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Any antiretroviral exposure
Number of subjects: 120
Study: 9020241

Group type: EXPERIMENTAL
Intervention: Computer-based dietary management system
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Self-reported reductions in intake of dietary saturated fat and cholesterol
Number of subjects: 814
Study: 7807189

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing trials
Number of subjects: 0
Study: 3286040

Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg three times daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (267 mg three times daily)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Aspirin daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Aspirin three times daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: All aspirin-containing regimens
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Overall operative mortality
Number of subjects: 555